Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Keratosis, Actinic 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Warts 1Squamous Intraepithelial Lesions 1Skin Neoplasms 1Radiodermatitis 1Parapsoriasis 1Non-Melanoma Skin Cancer (NMSC) 1Neoplasms 1Hypogonadism 1Hemangioma, Cavernous 1Hemangioma 1Head and Neck Cancer Patients Treated With Radiotherapy 1Fatigue 1Exanthema 1Eunuchism 1Dermatitis, Contact 1Carcinoma, Squamous Cell 1Carcinoma, Basal Cell 1Carcinoma 1Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Tamoxifen 12Early Intervention, Educational 7Methods 6Practice Guidelines as Topic 5Neoadjuvant Therapy 5Immunohistochemistry 5Counseling 5Chemotherapy, Adjuvant 5Anastrozole 5Standard of Care 4Specimen Handling 4Radiotherapy 4Psychiatric Rehabilitation 4Mastectomy, Segmental 4Mass Spectrometry 4Letrozole 4Educational Status 4Behavior Therapy 4Gene Expression Profiling 3Biopsy 3exemestane 2Telemedicine 2Taxes 2Surveys and Questionnaires 2Soybean Proteins 2Simvastatin 2Sentinel Lymph Node Biopsy 2Radiosurgery 2Radiation Dose Hypofractionation 2Radiation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Breast Carcinoma In Situ × Gels × Clear all
NCT04570956 2026-01-23

Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk

Mayo Clinic

Phase 2 Terminated
65 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡